Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Regulation of the endosomal SNX27-retromer by OTULIN.

Stangl A, Elliott PR, Pinto-Fernandez A, Bonham S, Harrison L, Schaub A, Kutzner K, Keusekotten K, Pfluger PT, El Oualid F, Kessler BM, Komander D, Krappmann D.

Nat Commun. 2019 Sep 20;10(1):4320. doi: 10.1038/s41467-019-12309-z.

2.

Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.

Vrzalikova K, Ibrahim M, Vockerodt M, Perry T, Margielewska S, Lupino L, Nagy E, Soilleux E, Liebelt D, Hollows R, Last A, Reynolds G, Abdullah M, Curley H, Care M, Krappmann D, Tooze R, Allegood J, Spiegel S, Wei W, Woodman CBJ, Murray PG.

Leukemia. 2019 Aug;33(8):2126. doi: 10.1038/s41375-019-0511-z.

PMID:
31239494
3.

Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells.

Rosenbaum M, Gewies A, Pechloff K, Heuser C, Engleitner T, Gehring T, Hartjes L, Krebs S, Krappmann D, Kriegsmann M, Weichert W, Rad R, Kurts C, Ruland J.

Nat Commun. 2019 May 28;10(1):2352. doi: 10.1038/s41467-019-10203-2.

4.

Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.

Cho JJ, Xu Z, Parthasarathy U, Drashansky TT, Helm EY, Zuniga AN, Lorentsen KJ, Mansouri S, Cho JY, Edelmann MJ, Duong DM, Gehring T, Seeholzer T, Krappmann D, Uddin MN, Califano D, Wang RL, Jin L, Li H, Lv D, Zhou D, Zhou L, Avram D.

Nat Commun. 2019 Feb 11;10(1):701. doi: 10.1038/s41467-019-08605-3.

5.

Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.

Vockerodt M, Vrzalikova K, Ibrahim M, Nagy E, Margielewska S, Hollows R, Lupino L, Tooze R, Care M, Simmons W, Schrader A, Perry T, Abdullah M, Foster S, Reynolds G, Dowell A, Rudzki Z, Krappmann D, Kube D, Woodman C, Wei W, Taylor G, Murray PG.

J Pathol. 2019 Jun;248(2):142-154. doi: 10.1002/path.5237. Epub 2019 Mar 22.

PMID:
30666658
6.

BCL10-CARD11 Fusion Mimics an Active CARD11 Seed That Triggers Constitutive BCL10 Oligomerization and Lymphocyte Activation.

Seeholzer T, Kurz S, Schlauderer F, Woods S, Gehring T, Widmann S, Lammens K, Krappmann D.

Front Immunol. 2018 Nov 20;9:2695. doi: 10.3389/fimmu.2018.02695. eCollection 2018.

7.

MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.

Bardet M, Seeholzer T, Unterreiner A, Woods S, Krappmann D, Bornancin F.

Biochem Biophys Res Commun. 2018 Nov 17;506(1):48-52. doi: 10.1016/j.bbrc.2018.10.029. Epub 2018 Oct 15.

PMID:
30336982
8.

Molecular architecture and regulation of BCL10-MALT1 filaments.

Schlauderer F, Seeholzer T, Desfosses A, Gehring T, Strauss M, Hopfner KP, Gutsche I, Krappmann D, Lammens K.

Nat Commun. 2018 Oct 2;9(1):4041. doi: 10.1038/s41467-018-06573-8.

9.

BCL10 - Bridging CARDs to Immune Activation.

Gehring T, Seeholzer T, Krappmann D.

Front Immunol. 2018 Jul 4;9:1539. doi: 10.3389/fimmu.2018.01539. eCollection 2018. Review.

10.

Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity.

Brenke JK, Popowicz GM, Schorpp K, Rothenaigner I, Roesner M, Meininger I, Kalinski C, Ringelstetter L, R'kyek O, Jürjens G, Vincendeau M, Plettenburg O, Sattler M, Krappmann D, Hadian K.

J Biol Chem. 2018 Aug 24;293(34):13191-13203. doi: 10.1074/jbc.RA118.002649. Epub 2018 Jun 27.

11.

GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.

Abd-Ellah A, Voogdt C, Krappmann D, Möller P, Marienfeld RB.

Sci Rep. 2018 Jan 22;8(1):1352. doi: 10.1038/s41598-018-19822-z.

12.

A Linear Diubiquitin-Based Probe for Efficient and Selective Detection of the Deubiquitinating Enzyme OTULIN.

Weber A, Elliott PR, Pinto-Fernandez A, Bonham S, Kessler BM, Komander D, El Oualid F, Krappmann D.

Cell Chem Biol. 2017 Oct 19;24(10):1299-1313.e7. doi: 10.1016/j.chembiol.2017.08.006. Epub 2017 Sep 14.

13.

S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.

Vrzalikova K, Ibrahim M, Vockerodt M, Perry T, Margielewska S, Lupino L, Nagy E, Soilleux E, Liebelt D, Hollows R, Last A, Reynolds G, Abdullah M, Curley H, Care M, Krappmann D, Tooze R, Allegood J, Spiegel S, Wei W, Woodman CBJ, Murray PG.

Leukemia. 2018 Jan;32(1):214-223. doi: 10.1038/leu.2017.275. Epub 2017 Sep 7. Erratum in: Leukemia. 2019 Aug;33(8):2126.

14.

YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-κB.

Schimmack G, Schorpp K, Kutzner K, Gehring T, Brenke JK, Hadian K, Krappmann D.

Elife. 2017 Feb 28;6. pii: e22416. doi: 10.7554/eLife.22416.

15.

Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-κB activation.

Bitzer A, Basler M, Krappmann D, Groettrup M.

Mol Immunol. 2017 Mar;83:147-153. doi: 10.1016/j.molimm.2017.01.019. Epub 2017 Jan 31.

PMID:
28157553
16.

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.

17.

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.

Wurster KD, Hummel F, Richter J, Giefing M, Hartmann S, Hansmann ML, Kreher S, Köchert K, Krappmann D, Klapper W, Hummel M, Wenzel SS, Lenz G, Janz M, Dörken B, Siebert R, Mathas S.

Leukemia. 2017 Mar;31(3):602-613. doi: 10.1038/leu.2016.238. Epub 2016 Aug 19.

18.

Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome.

Meininger I, Krappmann D.

Biol Chem. 2016 Dec 1;397(12):1315-1333. doi: 10.1515/hsz-2016-0216. Review.

PMID:
27420898
19.

Mechanisms of NF-κB deregulation in lymphoid malignancies.

Krappmann D, Vincendeau M.

Semin Cancer Biol. 2016 Aug;39:3-14. doi: 10.1016/j.semcancer.2016.05.002. Epub 2016 Jun 2. Review.

PMID:
27262792
20.

Development of new Malt1 inhibitors and probes.

Xin BT, Schimmack G, Du Y, Florea BI, van der Marel GA, Driessen C, Krappmann D, Overkleeft HS.

Bioorg Med Chem. 2016 Aug 1;24(15):3312-29. doi: 10.1016/j.bmc.2016.03.035. Epub 2016 Mar 28.

PMID:
27085674
21.

Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.

Howes A, O'Sullivan PA, Breyer F, Ghose A, Cao L, Krappmann D, Bowcock AM, Ley SC.

Biochem J. 2016 Jun 15;473(12):1759-68. doi: 10.1042/BCJ20160270. Epub 2016 Apr 12.

22.

Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells.

Meininger I, Griesbach RA, Hu D, Gehring T, Seeholzer T, Bertossi A, Kranich J, Oeckinghaus A, Eitelhuber AC, Greczmiel U, Gewies A, Schmidt-Supprian M, Ruland J, Brocker T, Heissmeyer V, Heyd F, Krappmann D.

Nat Commun. 2016 Apr 12;7:11292. doi: 10.1038/ncomms11292.

23.

Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.

Wilson DL, Meininger I, Strater Z, Steiner S, Tomlin F, Wu J, Jamali H, Krappmann D, Götz MG.

ACS Med Chem Lett. 2016 Jan 15;7(3):250-5. doi: 10.1021/acsmedchemlett.5b00401. eCollection 2016 Mar 10.

24.

Canonical NF-κB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response.

Sunami Y, Ringelhan M, Kokai E, Lu M, O'Connor T, Lorentzen A, Weber A, Rodewald AK, Müllhaupt B, Terracciano L, Gul S, Wissel S, Leithäuser F, Krappmann D, Riedl P, Hartmann D, Schirmbeck R, Strnad P, Hüser N, Kleeff J, Friess H, Schmid RM, Geisler F, Wirth T, Heikenwalder M.

Hepatology. 2016 May;63(5):1592-607. doi: 10.1002/hep.28435. Epub 2016 Mar 4.

25.

Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.

Bognar MK, Vincendeau M, Erdmann T, Seeholzer T, Grau M, Linnemann JR, Ruland J, Scheel CH, Lenz P, Ott G, Lenz G, Hauck SM, Krappmann D.

Oncogene. 2016 Aug 11;35(32):4269-81. doi: 10.1038/onc.2015.493. Epub 2016 Jan 18.

26.

Inhibition of Canonical NF-κB Signaling by a Small Molecule Targeting NEMO-Ubiquitin Interaction.

Vincendeau M, Hadian K, Messias AC, Brenke JK, Halander J, Griesbach R, Greczmiel U, Bertossi A, Stehle R, Nagel D, Demski K, Velvarska H, Niessing D, Geerlof A, Sattler M, Krappmann D.

Sci Rep. 2016 Jan 7;6:18934. doi: 10.1038/srep18934.

27.

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.

Nagel D, Bognar M, Eitelhuber AC, Kutzner K, Vincendeau M, Krappmann D.

Oncotarget. 2015 Dec 8;6(39):42232-42. doi: 10.18632/oncotarget.6273.

28.

In vitro detection of NEMO-ubiquitin binding using DELFIA and microscale thermophoresis assays.

Vincendeau M, Krappmann D, Hadian K.

Methods Mol Biol. 2015;1280:311-20. doi: 10.1007/978-1-4939-2422-6_18.

PMID:
25736757
29.

Detection of recombinant and cellular MALT1 paracaspase activity.

Nagel D, Krappmann D.

Methods Mol Biol. 2015;1280:239-46. doi: 10.1007/978-1-4939-2422-6_13.

PMID:
25736752
30.

Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas.

Eitelhuber AC, Vosyka O, Nagel D, Bognar M, Lenze D, Lammens K, Schlauderer F, Hlahla D, Hopfner KP, Lenz G, Hummel M, Verhelst SH, Krappmann D.

Chem Biol. 2015 Jan 22;22(1):129-38. doi: 10.1016/j.chembiol.2014.10.021. Epub 2014 Dec 31.

31.

MALT1 protease: equilibrating immunity versus tolerance.

Bertossi A, Krappmann D.

EMBO J. 2014 Dec 1;33(23):2740-2. doi: 10.15252/embj.201490217. Epub 2014 Oct 31. No abstract available.

32.

Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation.

Jeltsch KM, Hu D, Brenner S, Zöller J, Heinz GA, Nagel D, Vogel KU, Rehage N, Warth SC, Edelmann SL, Gloury R, Martin N, Lohs C, Lech M, Stehklein JE, Geerlof A, Kremmer E, Weber A, Anders HJ, Schmitz I, Schmidt-Supprian M, Fu M, Holtmann H, Krappmann D, Ruland J, Kallies A, Heikenwalder M, Heissmeyer V.

Nat Immunol. 2014 Nov;15(11):1079-89. doi: 10.1038/ni.3008. Epub 2014 Oct 5.

PMID:
25282160
33.

AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF-κB signaling upon T cell activation.

Schimmack G, Eitelhuber AC, Vincendeau M, Demski K, Shinohara H, Kurosaki T, Krappmann D.

Cell Commun Signal. 2014 Jul 22;12:49. doi: 10.1186/s12964-014-0049-7.

34.

Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.

Mc Guire C, Elton L, Wieghofer P, Staal J, Voet S, Demeyer A, Nagel D, Krappmann D, Prinz M, Beyaert R, van Loo G.

J Neuroinflammation. 2014 Jul 21;11:124. doi: 10.1186/1742-2094-11-124.

35.

Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.

Nagel D, Vincendeau M, Eitelhuber AC, Krappmann D.

Oncogene. 2014 Dec 11;33(50):5655-65. doi: 10.1038/onc.2013.565. Epub 2014 Jan 27. Review.

PMID:
24469030
36.

Shaping oncogenic NF-κB activity in the nucleus.

Krappmann D.

Blood. 2013 Sep 26;122(13):2146-7. doi: 10.1182/blood-2013-08-516864. No abstract available.

PMID:
24072847
37.

Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase.

Schlauderer F, Lammens K, Nagel D, Vincendeau M, Eitelhuber AC, Verhelst SH, Kling D, Chrusciel A, Ruland J, Krappmann D, Hopfner KP.

Angew Chem Int Ed Engl. 2013 Sep 23;52(39):10384-7. doi: 10.1002/anie.201304290. Epub 2013 Aug 14. No abstract available.

PMID:
23946259
38.

OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin.

Keusekotten K, Elliott PR, Glockner L, Fiil BK, Damgaard RB, Kulathu Y, Wauer T, Hospenthal MK, Gyrd-Hansen M, Krappmann D, Hofmann K, Komander D.

Cell. 2013 Jun 6;153(6):1312-26. doi: 10.1016/j.cell.2013.05.014.

39.

Progressive stages of mitochondrial destruction caused by cell toxic bile salts.

Schulz S, Schmitt S, Wimmer R, Aichler M, Eisenhofer S, Lichtmannegger J, Eberhagen C, Artmann R, Tookos F, Walch A, Krappmann D, Brenner C, Rust C, Zischka H.

Biochim Biophys Acta. 2013 Sep;1828(9):2121-33. doi: 10.1016/j.bbamem.2013.05.007. Epub 2013 May 17.

40.

Attacking MALT1 for ABC-DLBCL therapy.

Krappmann D.

Oncotarget. 2012 Dec;3(12):1489-90. No abstract available.

41.

The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO.

Müller-Rischart AK, Pilsl A, Beaudette P, Patra M, Hadian K, Funke M, Peis R, Deinlein A, Schweimer C, Kuhn PH, Lichtenthaler SF, Motori E, Hrelia S, Wurst W, Trümbach D, Langer T, Krappmann D, Dittmar G, Tatzelt J, Winklhofer KF.

Mol Cell. 2013 Mar 7;49(5):908-21. doi: 10.1016/j.molcel.2013.01.036. Epub 2013 Feb 28.

42.

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, Dörken B, Lenz P, Lenz G, Schendel DJ, Krappmann D.

Cancer Cell. 2012 Dec 11;22(6):825-37. doi: 10.1016/j.ccr.2012.11.002.

43.

A20 and CYLD do not share significant overlapping functions during B cell development and activation.

Chu Y, Soberon V, Glockner L, Beyaert R, Massoumi R, van Loo G, Krappmann D, Schmidt-Supprian M.

J Immunol. 2012 Nov 1;189(9):4437-43. doi: 10.4049/jimmunol.1200396. Epub 2012 Sep 21.

44.

Dlg3 trafficking and apical tight junction formation is regulated by nedd4 and nedd4-2 e3 ubiquitin ligases.

Van Campenhout CA, Eitelhuber A, Gloeckner CJ, Giallonardo P, Gegg M, Oller H, Grant SG, Krappmann D, Ueffing M, Lickert H.

Dev Cell. 2011 Sep 13;21(3):479-91. doi: 10.1016/j.devcel.2011.08.003.

45.

NF-κB essential modulator (NEMO) interaction with linear and lys-63 ubiquitin chains contributes to NF-κB activation.

Hadian K, Griesbach RA, Dornauer S, Wanger TM, Nagel D, Metlitzky M, Beisker W, Schmidt-Supprian M, Krappmann D.

J Biol Chem. 2011 Jul 22;286(29):26107-17. doi: 10.1074/jbc.M111.233163. Epub 2011 May 26.

46.

Signals from the nucleus: activation of NF-kappaB by cytosolic ATM in the DNA damage response.

Hadian K, Krappmann D.

Sci Signal. 2011 Jan 18;4(156):pe2. doi: 10.1126/scisignal.2001712.

PMID:
21245467
47.

Ubiquitin Conjugation and Deconjugation in NF-κB Signaling.

Düwel M, Hadian K, Krappmann D.

Subcell Biochem. 2010;54:88-99. doi: 10.1007/978-1-4419-6676-6_7. Review.

PMID:
21222275
48.

The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation.

Palkowitsch L, Marienfeld U, Brunner C, Eitelhuber A, Krappmann D, Marienfeld RB.

J Biol Chem. 2011 Mar 4;286(9):7522-34. doi: 10.1074/jbc.M110.155895. Epub 2011 Jan 3.

49.

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

Kloo B, Nagel D, Pfeifer M, Grau M, Düwel M, Vincendeau M, Dörken B, Lenz P, Lenz G, Krappmann D.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):272-7. doi: 10.1073/pnas.1008969108. Epub 2010 Dec 20.

50.

Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation.

Eitelhuber AC, Warth S, Schimmack G, Düwel M, Hadian K, Demski K, Beisker W, Shinohara H, Kurosaki T, Heissmeyer V, Krappmann D.

EMBO J. 2011 Feb 2;30(3):594-605. doi: 10.1038/emboj.2010.331. Epub 2010 Dec 14.

Supplemental Content

Loading ...
Support Center